Treatment of refractory stage IV metastatic breast cancer with weekly paclitaxel or weekly paclitaxel and Herceptin [trastuzumab] following autologous/syngeneic stem cell transplant.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2010
At a glance
- Drugs Trastuzumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2009 Actual end date (Oct 2001) added as reported by ClinicalTrials.gov.
- 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.